Skip to search formSkip to main contentSkip to account menu

BRL 26830A

Known as: BRL 26830, BRL-26830A, Benzoic acid, 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)-, methyl ester, (R*,R*)-(+-)-, (E)-2-butenedioate (2:1) (salt) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1992
Highly Cited
1992
The levels of beta 1- and beta 3-adrenoreceptor mRNAs in several rat tissues were determined simultaneously with a sensitive… 
1991
1991
The anti-obesity and anti-diabetic actions of BRL 26830A, beta 3-adrenoceptor agonist, (2 mg/kg administered intramuscularly… 
Highly Cited
1990
Highly Cited
1990
Glucose transport is decreased in skeletal muscle and adipose tissues of obese, hyperglycemic, insulin-resistant animals. Here we… 
1990
1990
The thermogenic beta 3-adrenoceptor agonist BRL 26830A has been shown to increase weight loss in dieting subjects but tremor was… 
Highly Cited
1988
Highly Cited
1988
A double blind placebo controlled study was carried out in 40 subjects newly referred for treatment for obesity to determine the… 
1987
1987
The nature of the substrate that fuels the thermogenic response to the novel beta-adrenoceptor agonist BRL 26830A has been… 
Highly Cited
1984
Highly Cited
1984
Recent studies suggest that thermogenesis in brown adipose tissue has an important role in the regulation of energy balance1–7… 
Highly Cited
1984
Highly Cited
1984
Studies on BRL 26830A in rodents have shown that thermogenic beta-adrenoceptor agonists have potential for the therapy of obesity… 
Highly Cited
1983
Highly Cited
1983
The effects of a novel compound, BRL 26830A, on energy balance in normal and obese mice have been investigated. BRL 26830A…